|
| | 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide Basic information |
| Product Name: | 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide | | Synonyms: | PF 04928473;SNX-2112 (PF-04928473);4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide;4-(6,6-Dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hyd;4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide;SNX-2112;SNX-2112;4-(6,6-DIMETHYL-4-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-INDAZOL-1-YL)-2-((1R,4R)-4-HYDROXYCYCLOHEXYLAMINO)BENZAMIDE;2-[(trans-4-Hydroxycyclohexyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]benzamide | | CAS: | 908112-43-6 | | MF: | C23H27F3N4O3 | | MW: | 464.48 | | EINECS: | | | Product Categories: | Inhibitors;Inhibitor | | Mol File: | 908112-43-6.mol |  |
| | 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide Chemical Properties |
| Melting point | 265-266℃ | | Boiling point | 619.8±55.0 °C(Predicted) | | density | 1.47 | | storage temp. | Store at -20°C | | solubility | ≥23.05 mg/mL in DMSO; insoluble in H2O; ≥9.6 mg/mL in EtOH with gentle warming and ultrasonic | | form | solid | | pka | 15.07±0.50(Predicted) |
| | 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide Usage And Synthesis |
| Uses | SNX-2112 is a selective heat shock protein 90 (Hsp90) inhibitor which can exert a potent anticancer activity. Studies demonstates that SNX-2112 can exhibit a potent anticancer activity against B16 mel
anoma cells both in vitro and in vivo, by inhibiting cell proliferation and inducing cell cycle arrest and apoptosis in a mechanism dependent on the degredation of Hsp90 client proteins. | | Uses | SNX-2112 is a selective heat shock protein 90 (Hsp90) inhibitor which can exert a potent anticancer activity. Studies demonstates that SNX-2112 can exhibit a potent anticancer activity against B16 melanoma cells both in vitro and in vivo, by inhibiting cell proliferation and inducing cell cycle arrest and apoptosis in a mechanism dependent on the degredation of Hsp90 client proteins. | | target | Hsp90α |
| | 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide Preparation Products And Raw materials |
|
